 Connection
Angus Macnicol to Cell Line, Tumor
This is a "connection" page, showing publications Angus Macnicol has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.409 |
|
|
|
-
Urbaniak A, Reed MR, Heflin B, Gaydos J, Pi?a-Oviedo S, Jedrzejczyk M, Klejborowska G, Stepczynska N, Chambers TC, Tackett AJ, Rodriguez A, Huczynski A, Eoff RL, MacNicol AM. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer. Biomed Pharmacother. 2022 Sep; 153:113440.
Score: 0.153
-
Urbaniak A, Reed MR, Fil D, Moorjani A, Heflin S, Antoszczak M, Sulik M, Huczynski A, Kupsik M, Eoff RL, MacNicol MC, Chambers TC, MacNicol AM. Single and double modified salinomycin analogs target stem-like cells in 2D and 3D breast cancer models. Biomed Pharmacother. 2021 Sep; 141:111815.
Score: 0.142
-
MacNicol AM, Hardy LL, Spencer HJ, MacNicol MC. Neural stem and progenitor cell fate transition requires regulation of Musashi1 function. BMC Dev Biol. 2015 Mar 18; 15:15.
Score: 0.092
-
Penthala NR, Bommagani S, Janganati V, MacNicol KB, Cragle CE, Madadi NR, Hardy LL, MacNicol AM, Crooks PA. Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression. Eur J Med Chem. 2014 Oct 06; 85:517-25.
Score: 0.022
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|